A λ-Carrageenan-Enriched Sulfated Galactan from Gigartina radula Attenuates Atopic Dermatitis via Coordinated Anti-Inflammatory and Immunomodulatory Mechanisms
Marine Drugs · 2026
DOI: 10.3390/md24030119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2026. Verfasst von Kexin Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, Ministry of Education, School of Medicine and Pharmacy…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Rhodophyta, Anti-Inflammatory Agents, Carrageenan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Key R&D Program, Fundamental Research Funds for the Central Universities, Taishan Scholar Project.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by immune dysregulation and epidermal barrier dysfunction. Current therapeutic options are often limited by safety concerns or suboptimal tolerability. In this study, we isolated and structurally characterized GRB-H—a λ-carrageenan-enriched sulfated hybrid galactan from the marine red alga Gigartina radula—as a complex polysaccharide containing κ-, ι-, μ-, ν-, and λ-carrageenan structural units, and systematically evaluated its anti-AD potential using both in vitro and in vivo models. In vitro, GRB-H significantly suppressed lipopolysaccharide (LPS)-induced nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in RAW 264.7 macrophages, and reduced 2,4-dinitrochlorobenzene (DNCB)-evoked TNF-α and IL-1β expression in HaCaT keratinocytes. In a DNCB-induced murine model of AD, topical application of GRB-H markedly ameliorated skin inflammation, epidermal hyperplasia, and dermal immune cell infiltration. GRB-H treatment lowered total serum immunoglobulin E (IgE) levels, restored the imbalanced Th1/Th2 cell ratio in the spleen, and downregulated the mRNA expression of key inflammatory cytokines—including TNF-α, IL-4, IL-5, IL-31, and interferon-γ (IFN-γ)—in lesional skin. Collectively, these findings demonstrate that GRB-H alleviates AD symptoms through coordinated local anti-inflammatory and systemic immunomodulatory actions, highlighting its promise as a marine-derived candidate for the topical management of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Qingdao Key Laboratory of Respiratory Comorbidity Remodeling and Precision Prevention, Qingdao Municipal Hospital, Qingdao 260071, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao 266237, China.
ORCID-Profile: Guangli Yu
Förderung
- Shandong Provincial Key R&D Program
- Fundamental Research Funds for the Central Universities
- Taishan Scholar Project
- National Natural Science Foundation of China
Zitieren
APA
Du, K., Liang, S., Wu, Z., Wang, Y., Gao, P., Han, W., Lv, Y., Yu, G., & Li, G. (2026). A λ-Carrageenan-Enriched Sulfated Galactan from Gigartina radula Attenuates Atopic Dermatitis via Coordinated Anti-Inflammatory and Immunomodulatory Mechanisms. Marine Drugs. https://doi.org/10.3390/md24030119
Vancouver
Du K, Liang S, Wu Z, Wang Y, Gao P, Han W, et al. A λ-Carrageenan-Enriched Sulfated Galactan from Gigartina radula Attenuates Atopic Dermatitis via Coordinated Anti-Inflammatory and Immunomodulatory Mechanisms. Marine Drugs. 2026. doi:10.3390/md24030119
BibTeX
@article{Du2026,
author = {Du, Kexin and Liang, Shuo and Wu, Zijing and Wang, Yujing and Gao, Pengcheng and Han, Wei and Lv, Youjing and Yu, Guangli and Li, Guoyun},
title = {A λ-Carrageenan-Enriched Sulfated Galactan from Gigartina radula Attenuates Atopic Dermatitis via Coordinated Anti-Inflammatory and Immunomodulatory Mechanisms},
journal = {Marine Drugs},
year = {2026},
doi = {10.3390/md24030119}
}
EUVIMED